Asparaginase unveils glutamine-addicted AML

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) cells exhibit metabolic dependencies crucial for their proliferation and survival.
• Glutamine metabolism plays a significant role in cancer cell growth, particularly in protein synthesis pathways.
• The mammalian target of rapamycin (mTOR) pathway is a key regulator of cell growth and protein synthesis, often dysregulated in cancer.

Purpose of the Study:

• To investigate the dependence of acute myeloid leukemia (AML) cells on glutamine for protein synthesis.
• To explore the potential of the enzyme asparaginase as a therapeutic agent for AML by targeting glutamine metabolism.
• To elucidate the mechanism by which asparaginase may exert its anti-leukemic effects in AML.

Main Methods:

• Utilized various acute myeloid leukemia (AML) cell lines for in vitro studies.
• Analyzed primary AML patient samples to assess therapeutic relevance.
• Included CD34+ stem cells from healthy donors as controls.
• Assessed the impact of asparaginase on glutamine levels, mTOR signaling, and protein synthesis.

Main Results:

• AML cells demonstrate a significant dependence on glutamine for protein synthesis, downstream of mTOR signaling.
• Asparagine depletion by asparaginase leads to reduced glutamine levels in AML cells.
• This reduction in glutamine inhibits mTOR signaling, suppresses protein synthesis, and results in decreased cancer cell viability.
• These effects were observed across AML cell lines, primary samples, and healthy donor stem cells.

Conclusions:

• Asparaginase may represent a promising therapeutic strategy for acute myeloid leukemia (AML).
• The therapeutic benefit of asparaginase in AML appears to stem from its off-target effects on glutamine metabolism, rather than its canonical enzymatic activity.
• Targeting glutamine-dependent protein synthesis via asparaginase offers a novel approach to AML treatment by inhibiting mTOR signaling and inducing cancer cell death.